ADA and diabetes mellitus: Thus, PEG-ADA may not be suitable for prevention or treatment of beta-cell dysfunction in diabetes, and other and more beta-cell specific strategies for improved adenosine disposal, for example by using miRNA target blockers, might be more attractive alternatives.